Multidrug regimens for treatment of older patients with metastatic pancreatic cancer.
Combination chemotherapy
Lung metastasis
Metastatic pancreatic cancer
Older patients
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
25
02
2020
revised:
03
06
2020
accepted:
04
06
2020
pubmed:
8
7
2020
medline:
18
12
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Older patients with metastatic pancreatic adenocarcinoma (MPDAC) are under-represented in clinical trials. Our single-center, retrospective study enrolled MPDAC patients ≥ 70 treated with chemotherapy RESULTS: 105 patients were divided in groups based on the received treatments: 44 gemcitabine or capecitabine monotherapy (A), 34 nabpaclitaxel-gemcitabine (B) 27 4-drugs combinations (gemcitabine, cisplatin, capecitabine plus either nab-paclitaxel or epirubicin or docetaxel) (C). Group A: median age was 78 (70-87) and Karnofsky performance status (KPS) ≥80 was found in 84% of patients; Group B: median age 77 (71-84) and KPS ≥ 80 in 88% of patients; Group C: median age 73 (70-78) and KPS ≥ 80 in 93% of patients. Median OS was 7.9, 11.7 and 14.2 months in group A, B and C respectively; 1 and 2-year OS were 27% and 8% in group A; 44% and 5% in group B; 52% and 22% in group C. When lung metastatic only patients were excluded, patients <75 and ≥ 75 had similar OS in group A (6.4 vs 5.6 months) and in group B (12.3 vs 11.1 months). In group B grade 3 thrombocytopenia, fatigue and peripheral neuropathy were more frequent in patients ≥ 75. In older patients, combination chemotherapy shows acceptable feasibility and promising efficacy.
Sections du résumé
BACKGROUND AND AIMS
Older patients with metastatic pancreatic adenocarcinoma (MPDAC) are under-represented in clinical trials.
METHODS
Our single-center, retrospective study enrolled MPDAC patients ≥ 70 treated with chemotherapy RESULTS: 105 patients were divided in groups based on the received treatments: 44 gemcitabine or capecitabine monotherapy (A), 34 nabpaclitaxel-gemcitabine (B) 27 4-drugs combinations (gemcitabine, cisplatin, capecitabine plus either nab-paclitaxel or epirubicin or docetaxel) (C). Group A: median age was 78 (70-87) and Karnofsky performance status (KPS) ≥80 was found in 84% of patients; Group B: median age 77 (71-84) and KPS ≥ 80 in 88% of patients; Group C: median age 73 (70-78) and KPS ≥ 80 in 93% of patients. Median OS was 7.9, 11.7 and 14.2 months in group A, B and C respectively; 1 and 2-year OS were 27% and 8% in group A; 44% and 5% in group B; 52% and 22% in group C. When lung metastatic only patients were excluded, patients <75 and ≥ 75 had similar OS in group A (6.4 vs 5.6 months) and in group B (12.3 vs 11.1 months). In group B grade 3 thrombocytopenia, fatigue and peripheral neuropathy were more frequent in patients ≥ 75.
CONCLUSIONS
In older patients, combination chemotherapy shows acceptable feasibility and promising efficacy.
Identifiants
pubmed: 32631650
pii: S1590-8658(20)30269-3
doi: 10.1016/j.dld.2020.06.006
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-121Informations de copyright
Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest MR reports grants, personal fees, and non-financial support from Celgene; grants and personal fees from Baxalta; grants and personal fees from Merck Serono; grants from Helsinn; and personal fees from Lilly, Pfizer, AstraZeneca, NovoCure, Halozyme, Novartis, and Shire. LG reports personal fees from Roche, Pfizer, Boehringer Ingelheim, Celgene, Taiho Pharmaceutical, Synthon, AstraZeneca, Genomic Health, Merck Sharp & Dohme, Synaffix, Eli Lilly, Odonate Therapeutics, Sandoz, Onkaido, Oncolytics Biotech, ADC Therapeutics, and Seattle Genetics. All other authors declare no competing interests.